% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

whippersnapper65 96 posts  |  Last Activity: 10 hours ago Member since: Jun 20, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    The good news about CDX-301 is that

    by trufflesdrive Jun 5, 2016 3:09 PM
    whippersnapper65 whippersnapper65 Jun 5, 2016 8:34 PM Flag

    The rise to $38 was also in part due to speculation about CDX-1135, which was in a pilot study that was discontinued due to enrolling only one person with an ultra-rare disease.

    I agree with you that $38 will be small potatoes if Glemba, Varli and 301 are all approved.

    The market doesn't understand what Celldex has.

    Sentiment: Strong Buy

  • Reply to

    The good news about CDX-301 is that

    by trufflesdrive Jun 5, 2016 3:09 PM
    whippersnapper65 whippersnapper65 Jun 5, 2016 7:53 PM Flag

    The science guys, led by Tibor Keler and Tom Davis, have clearly done their homework well: predicting at least a decade ago that combination cancer immunotherapy is the future of cancer treatment and assembling a pipeline of promising targeted therapies with foresight regarding which targets had multiple combinatory applications.

    Varli could combine with many therapies and might be particularly effective in conjunction with checkpoint inhibitors.

    CDX-301 could combine with any therapy whose effectiveness would be increased by boosting the number of dendritic cells.

    Glemba may turn out to be effective against the numerous cancers that have high gpNMB expression.

    Any one of those by itself would be a blockbuster treatment if approved. The market does not at all appreciate the profit potential of Celldex's pipeline.

    Strong buy and hold.

    Sentiment: Strong Buy

  • Reply to

    The good news about CDX-301 is that

    by trufflesdrive Jun 5, 2016 3:09 PM
    whippersnapper65 whippersnapper65 Jun 5, 2016 4:45 PM Flag

    Like Varli, CDX-301 could be used in combination with a great many treatments in order to increase their effectiveness. Wherever an increase in dendritic cells would help prime the immune system to fight disease, CDX-301 could make existing therapies more potent.

    Sentiment: Strong Buy

  • Reply to


    by professorguy001 Jun 4, 2016 7:44 PM
    whippersnapper65 whippersnapper65 Jun 5, 2016 10:52 AM Flag

    One way in which the news is different is that the poster provides updated information on disease recurrence:

    "Disease recurred in 13 of 60 pts (Cohort 1 (7 pts),
    Cohort 2 (6 pts). Two of the 13 pts progressed prior
    to completing 4 cycles of treatment."

    A 21.6% recurrence rate in this patient population is probably laudable. However, there was no significant difference between the two cohorts regarding recurrence, so the addition of CDX-301 and its contribution to potent immune responses didn't result in a difference between the cohorts regarding disease recurrence, at least not at this time. The poster didn't state which patients had disease recurrence nor what their melanoma stages were at the time of study entry.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 Jun 4, 2016 5:05 PM Flag

    Recall that Celldex made this statement in its 1Q earnings report:

    "Given that hematopoietic stem cell transplantation is outside of Celldex's core focus, in an effort to prioritize human and capital resources, the Company has decided not to advance CDX-301 in this particular indication at this time and instead to focus near-term efforts on its potential role in combination immunotherapy."

    Management knew about today's CDX-301 data when it issued the earnings report; they must have big plans for further development of that asset in combination immunotherapy given the results released today.

    Sentiment: Strong Buy

  • Reply to

    "Look at my African-American over here"

    by cyoung8404 Jun 4, 2016 4:46 AM
    whippersnapper65 whippersnapper65 Jun 4, 2016 12:04 PM Flag

    No, Ray, fug can't do better. He's on ignore, so I'm not reading his drivel, but all the left can do is hurl epithets. They cannot argue in defense of their positions because their stances won't withstand reasoned scrutiny. All they can do is yell, demean, riot, threaten and insult. They smugly believe they are superior, and the totalitarian tendency that is part and parcel of leftist sentiment leads them to construe their ideological opponents falsely as evil. All the left can do is divide the world according to race/class/gender. The left doesn't think rationally, which is the primary reason why the left is such a dangerous force: the left eschews wisdom and truth. In place of wisdom and truth the left brings foolishness and lies. And when they get power they outlaw disagreement with them. We are seeing it happen in this country where the left is attempting to outlaw and suppress conservatism and conservatives. Just look at all the riots that have occurred in this country, instigated by leftist agitators with either the tacit or explicit endorsement of the most senior Democrat government officials. Leftism is a mental disorder.

  • whippersnapper65 whippersnapper65 Jun 3, 2016 5:05 PM Flag

    The political taunts (it's not a discussion) on this message board have become childish. If the posters here met in person, the leftists would start a riot and violently attack conservatives just like they did in San Jose and in other places in Commifornia/Mexifornia.

    It's obvious that the leftists are quite afraid of a Trump electoral victory, otherwise they wouldn't be posting ten new threads or more per day here plus taking pot shots in other threads. It's obvious they are self-loathing narcissists looking for attention, which they misconstrue as validation.

    Just do what I do: put all the leftists and the most frequently tiresome posters who are not leftists on ignore. It cleans up the message board view very nicely.

  • Reply to

    Close At The High Of The Day

    by j20tower20 Jun 2, 2016 4:03 PM
    whippersnapper65 whippersnapper65 Jun 3, 2016 4:11 PM Flag

    And today, the very next day, it closed at the low of the day, J20, erasing all of the previous day's gains.

    TA is pointless with CLDX.

    You're either in this for the long term because you believe the pipeline will be commercialized and extremely profitable, making Celldex a paradigm-changing biotech company, or you don't know what you're doing here.

    Sentiment: Strong Buy

  • Reply to

    Basing for a new run

    by remingtonredneck72 Jun 3, 2016 12:30 PM
    whippersnapper65 whippersnapper65 Jun 3, 2016 1:52 PM Flag

    If CLDX had advanced you would have written that that was to be expected after breaking through $5 resistance and that CLDX was on its way to filling the gap to $7.

    Give up the TA; it has no predictive value.

    Sentiment: Strong Buy

  • Reply to

    5:00 Should Start Institutional Buying

    by j20tower20 Jun 2, 2016 8:21 PM
    whippersnapper65 whippersnapper65 Jun 2, 2016 9:12 PM Flag

    Institutions already own 88% of outstanding shares.

    Sentiment: Strong Buy

  • Reply to

    blue cross

    by rumbleinstreet Jun 2, 2016 10:25 AM
    whippersnapper65 whippersnapper65 Jun 2, 2016 6:15 PM Flag

    Not only that, grey, but deceptive workarounds by insurance providers are being used to give the illusion of good health coverage for the premium charged. Some people have learned that when they went to a hospital that was in their network, and thus presumably provided covered care, some specialists such as anesthesiologists are not in the provider's network but are independent contractors at the hospital; so patients are getting separately billed for the work of the independent contractors, which is not covered by the health insurance that they purchased -- they have to pay for those costs separately and out of pocket.

    Patients need to ask not only whether the doctor, the hospital and nursing staff are in the network and covered by the policy but whether every person that will provide them with any aspect of care is covered by their insurance policy.

    There are all sorts of hidden costs and shenanigans in Odumbacare, which was passed through the maneuver of reconciliation (which didn't apply to that category of proposed legislation) and is an unconstitutional law on top of it all, regardless of what that turncoat John Roberts stated in his absurd opinion. I wonder who got to him and what they threatened him with to make him change his mind at the 11th hour.

    Undoing Odumbacare will be one of the things President Trump should make a priority during his first 90 days in office. Begin dismantling that Marxist traitor's destructive "legacy" brick-by-brick. Time to make America great again.

  • Reply to

    Thank You Billionaires

    by invest83838 Jun 2, 2016 4:21 PM
    whippersnapper65 whippersnapper65 Jun 2, 2016 4:57 PM Flag

    Soon we will be thanking the shorts. Short shares equal to 25% of the float, all of which should have covered below $4 when they had the chance, when they cover will propel the share price back into double-digits, where it should be and would be were it not for the large short position.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 Jun 2, 2016 1:55 PM Flag

    long_vrts2, are you implying that this revised expanded access program appears to be quasi-approval through the back door? So patients who want an experimental treatment could access it if they could pay for it and companies would be permitted to profit from the sale of the drug?

    Seems like an almost worthless consolation prize to me. If Rintega works, then approve it for commercial sale. If it doesn't work, then why offer it in compassionate use programs? The FDA can't have it both ways.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 May 31, 2016 7:07 PM Flag

    No Celldex insiders have sold any shares except Avery Catlin, who I believe is the oldest member of executive management and very near retirement, and he has only sold a fraction of his shares. In the first quarter Catlin exercised some options when CLDX was trading below $4, but he didn't sell any of those shares; he's a finance guy who understands the tax advantages of exercising options when the tax liability is low and he decided to take advantage of the temporary low valuation for the shares that he intends to sell later for a much, much higher price.

    Furthermore, Celldex management has many hundreds of thousands of derivatively owned shares in the form of incentive stock options that are out of the money because their exercise prices are at $8, $13, $17 and $24 or thereabouts. Management will not make millions upon millions unless they get the share price back into the $30s.

    Nothing you stated applies to Celldex. You are an ignorant basher whom I am now ignoring. CLICK.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 May 31, 2016 4:58 PM Flag

    The executive management team and BOD made a collective show of confidence by buying shares on the open market in September 2010 after Pfizer pulled out of its collaboration deal. In August and September of last year Ellberger and Marucci bought shares on the open market during the biotech sector meltdown.

    So management has purchased shares in the past as a show of confidence. It does raise the question why not now? Why not when the share price is below $5 for the first time in four years? If the company's pipeline is that good, why not?

    The fact that the company is seeking a VP/SVP of Global Regulatory Affairs might be an indication that management is privy to nonpublic material information that would put them on the wrong side of insider trading laws were they to purchase shares at this time.

    Sentiment: Strong Buy

  • whippersnapper65 whippersnapper65 May 31, 2016 4:51 PM Flag

    I noticed that too.

    Ask the 7,8,9,10+ year survivors who would have been dead by now were it not for Rintega whether it has been proven ineffective.

    Sentiment: Strong Buy

3.43-0.05(-1.44%)Aug 30 4:00 PMEDT